^
Association details:
| Biomarker: | EGFR V769A |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib
Excerpt:
...the patient showed a good clinical response to erlotinib after paclitaxel/cisplatin first-line and docetaxel second-line chemotherapies...Therefore, we suggest that this rare mutation (p.V769A) may be a sensitive EGFR mutation in NSCLC.
DOI:
10.1007/s12032-014-0036-2
